In our previous study, we described synchronized activity of organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter in the passage of organic cations across the rat placenta and the role of these transporters in fetal defense; in this study, we hypothesized that changes in placental levels of OCT3 and MATE1 throughout gestation might affect the fetal protection and detoxification. Using quantitative RT-PCR, Western blot analysis, and immunohistochemistry, we were able to detect Oct3/OCT3 and Mate1/MATE1 expression in the rat placenta as early as on Gestation Day (gd) 12 with increasing tendency toward the end of pregnancy. Comparing first versus third trimester human placenta, we observed stable expression of OCT1 and decreasing expression of OCT2 and OCT3 isoforms. Contrary to the current literature, we were able to detect also MATE1/MATE2 isoforms in the human placenta, however, with considerable inter-and intraindividual variability. Using infusion of 1-methyl-4-phenylpyridinium (MPP + ), a substrate of OCT and MATE transporters, into pregnant dams, we investigated the protective function of the placenta against organic cations at different gds. The highest amount of MPP + reached the fetus on gd 12 while from gd 15 onward, maternal-to-fetal transport of MPP + decreased significantly. We conclude that increased expression of placental OCT3 and MATE1 along with general maturation of the placental tissues results in significantly lower transport of MPP + from mother to fetus. In contrast, decreasing expression of OCT3 and MATE1 in human placenta indicates these transporters may play a role in fetal protection preferentially at earlier stages of gestation.
INTRODUCTION
The placenta, among its many other functions, mediates the transfer of endogenous compounds as well as xenobiotics between the mother and her developing fetus; it is also an important organ of fetal protection and detoxification. To fulfill these roles, the placenta is equipped with many transport systems localized to both the maternal-and fetal-facing membranes [1, 2] . Understanding the exact mechanism(s) of placental transporters and their role in transplacental pharmacokinetics will aid in optimization of pharmacotherapy of pregnant women and prediction of toxicity risks for the fetus. While the placental expression and function of the drug transporters of the ATP-binding cassette (ABC) family, such as P-glycoprotein and breast cancer resistance protein, have been studied extensively, significantly less information has been gathered on the solute carrier (SLC) transporters [1] .
The SLC family is the largest of all the transporter families, consisting of over 300 members. Some SLC transporters are substrate-specific, preferentially mediating transport of endogenous compounds such as amino acids, nucleosides, and sugars. Others, on the other hand, show wide substrate specificity, recognizing a broad spectrum of molecular structures and dimensions. These are called polyspecific transporters and have been shown to play a major role in drug disposition [3] . In particular, SLC transporters have been described as important components of eliminatory pathways for cations and anions in excretory organs. For example, vectorial transport of organic cations mediated by organic cation transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs) was described in the proximal tubules of the kidney and hepatocytes [4, 5] , suggesting that OCTs and MATEs work in a concert manner; OCTs being responsible for uptake and MATEs for efflux of organic cations [5] [6] [7] .
In the placenta, SLC transporters mainly facilitate uptake of hydrophilic or charged molecules by the trophoblast cells; once in the trophoblast, the substrates are either utilized for the placenta's own metabolic needs (e.g., de novo synthesis of placental hormones) or pumped out of the trophoblast cell by another SLC or ABC transporter such as MATE or Pglycoprotein (for a review, see [1] ). In our previous study [8] , we described the expression and localization of organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter in the rat term placenta. Using immunohistochemical visualization, we revealed preferential localization of OCT3 on the basolateral, that is, fetus-facing side of the placenta, whereas MATE1 was located in the labyrinth area predominantly on the apical (i.e., maternal) side of the placenta. Furthermore, using the technique of dually perfused rat term placenta, we demonstrated that OCT3, in a concentration-dependent manner, takes up organic cations from the fetal circulation into the placenta and MATE1 is responsible for their efflux to the maternal circulation, even against a concentration gradient. We, therefore, proposed that OCT3 and MATE1 form an efficient transplacental eliminatory pathway for organic cations and play an important role in fetal protection and detoxification [8] .
Pregnancy is a dynamic process where the physiological systems of both the mother and her developing fetus change continuously. Importantly, most data on placental drug transporters are obtained from term placentas. However, variations in expression of placental drug transporters and activity throughout pregnancy have been observed in several mammal species. Regarding SLC transporters, several papers reported on intraindividual variability of Oct3 expression in the murine placenta, concluding that the levels of expression decline toward the end of gestation [9, 10] ; however, no information on intraindividual changes in OCTs and/or MATEs expression in the human and rat placenta is available to date. Furthermore, little is known about expression and function of these transporters in fetal tissues.
In this study we hypothesized that changes in placental levels of OCT3 and/or MATE1 transporters throughout gestation might affect their transport capacity and, subsequently, provide variable fetal protection throughout fetal development. Therefore, we investigated the expression of OCT1, OCT2, OCT3, MATE1, and MATE2 transporters in the rat and human placenta and rat fetal tissues at different stages of pregnancy. In addition, using the infusion of 1-methyl-4-phenylpyridinium (MPP þ ), a model toxin and well-established substrate of OCT3 and MATE1, into the pregnant rat, we also studied the protective effect of the placenta against organic cations at different stages of gestation.
MATERIALS AND METHODS

Reagents and Chemicals
MPP
þ and the loading control for Western blot analysis, rabbit polyclonal anti-b-actin antibody (42-45 kDa), were purchased from Sigma-Aldrich. The radiolabeled [ 3 H] MPP þ was obtained from Perkin Elmer Life and Analytical Sciences. Rabbit polyclonal antibodies anti-Oct3, directed to the OCT3 (BS3359) (70 kDa) and anti-Mate1 directed to MATE1 (sc-138983) (65 kDa) were obtained from Bioworld Technology, Inc. and Santa Cruz Biotechnology, Inc., respectively. Horseradish peroxidase-linked donkey antirabbit immunoglobulin G (IgG), F (ab 0 ) 2 fragment, was purchased from GE Healthcare. All the other chemicals were of analytical grade.
Animals
Female Wistar rats were used for all the experiments. Pregnant rats were purchased from Biotest and maintained at 12L:12D standard conditions with water and pellets ad libitum. All the experiments were approved by the ethical committee of the Faculty of Pharmacy in Hradec Kralove (Charles University in Prague, Czech Republic) and were carried out in accordance with the Guide for the Care and Use of Laboratory Animals (1996) and the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes (Strassbourg, 1986) .
Gestation Day (gd) 0 was established upon detection of a copulatory plug of sperm after overnight mating. Experiments were performed on gds 12, 15, 18, and 21 using three to four dams in each group. Fasted rats were anesthetized with pentobarbital (nembutal; Abbott Laboratories) in a dose of 40 mg/kg administered into the tail vein.
RNA Isolation and Real-Time RT-PCR Analysis in the Rat Placenta and Fetal Tissues
Four rat placentas were randomly dissected from four dams on each gd (12, 15, 18, and 21) . The kidney, liver, brain, and intestine were sampled from three to four randomly selected fetuses of each dam on gds 18 and 21. The maternal kidney was selected as a positive control. The organs were frozen in liquid nitrogen immediately after dissection and stored at À708C until analysis. Expression of Oct1, Oct2, Oct3, Mate1, and Mate2 mRNA was analyzed using quantitative RT-PCR (qRT-PCR) on 7500HT Fast Real-Time PCR System (Applied Biosystems) as described previously [8] . Total RNA was isolated from collected tissue samples using the Qiagen RNeasy Mini Kit (Bio-Consult Laboratories); the purity of the isolated RNA was checked by the absorbance ratio at 260 and 280 nm (A260/A280) and RNA integrity was confirmed by electrophoresis on a 1% agarose gel. RNA was converted into cDNA via highcapacity cDNA reverse transcription kit (Life Technologies); the reaction mixture contained 30 ng of analyzed cDNA. The amplification of each sample was performed in triplicate using TaqMan Fast Universal PCR Master Mix and predesigned TaqMan Gene Expression Assay for Oct1 (Slc22a1, Rn00562250_m1), Oct2 (Slc22a2, Rn00580893_m1), Oct3 (Slc22a3, Rn00570264_m1), Mate1 (Slc47a1, Rn01460731_m1), and Mate2 (Slc47a2, Rn02601013_m1) provided by Life Technologies. The time-temperature profile used in the fast mode was 958C for 3 min followed by 40 cycles at 958C for 7 sec and 608C for 25 sec. For greater precision of the mRNA quantification results, two housekeeping genes were selected by the geNorm algorithm [11] : Ywhaz (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) (Ywhaz_Q1, NM_013011, exon5/ exon6; GENERI BIOTECH Ltd.) was used because of its stable expression in the placenta [12] and Gapdh (glyceraldehyde-3-phosphate dehydrogenase) (4352338E; Life Technologies) was used because of its stability in other organs [13] . Expression values of each sample were obtained as described previously [11, 14] . The expression data are normalized by the geometric mean of Gapdh and Ywhaz expressions and presented as a ratio between target mRNA and housekeeping mRNA.
RNA Isolation and Real-Time RT-PCR Analysis in the Human Placenta
All the human placentas were obtained from uncomplicated pregnancies in accordance with ethical standards at University Hospital, Hradec Kralove. All the participants provided written informed consent, and their details are summarized in Table 1 . Ten term placentas were collected following elective cesarean section at term (38-40 wk of gestation) and seven first trimester placentas were acquired from interruption of the pregnancy between 9 and 12 wk of gestation. The placental samples were frozen in liquid nitrogen immediately after surgery and stored at À708C until analysis. Total RNA was isolated from preweighed placenta using Tri Reagent solution (Molecular Research Centre) according to the manufacturer's instructions. The purity of the isolated RNA was checked by A260/A280, and RNA integrity was confirmed by electrophoresis on a 1% agarose gel. The concentration of RNA was calculated by A260 measurement. RNA was converted into cDNA using the Tetro cDNA Synthesis Kit (Bioline). Real-time PCR analysis of OCT1, OCT2, OCT3, MATE1, and MATE2 mRNA expression was performed on iCycler machine (Bio-Rad). Complementary DNA (40 ng) was amplified using 23 Probe Master Mix (GENERI BIOTECH Ltd.) and predesigned TaqMan PCR assays for OCT1 (hSLC22A1_Q3), OCT2 (hSLC22A2_Q1), OCT3 (hSLC22A1_Q2), MATE1 (hSLC47A1_Q1), and MATE2 (hSLC47A2_Q1). For greater precision of the mRNA quantification, four housekeeping genes were selected: B2M (beta-2-microglobulin) because of its high and relatively stable expression in the term placenta [12] , HPRT (hypoxanthine phosphoribosyl-transferase 1) and TBP (TATA box binding protein) for their stable expression in the term placenta [12] , and 18S rRNA (hRN18S1_Q1) because of its high and consistent expression throughout gestation and low variability between individuals [15] [16] [17] . All the assays were purchased from GENERI BIOTECH Ltd. The amplification of each sample was performed in triplicate. The time-temperature profile used was 958C for 3 min followed by 50 cycles at 958C for 15 sec and 608C for 45 sec. Expression values of each sample were obtained as described previously [11, 14] .
Membrane Preparation
A modified method of Chen et al. [18] was used for the membrane preparation. Briefly, the maternal kidney, placenta, fetal brain, and intestine were minced in ice-cold RIPA buffer (Sigma-Aldrich), containing 0.5 lg/ml leupeptin, 0.5 lg/ml pepstatin, 2 lg/ml aprotinin, and 50 lg/ml benzamidine, and then were homogenized using a Magna Lyser Instrument (Roche AHMADIMOGHADDAM ET AL. Diagnostics) at 6500 rpm for 2 3 30 seconds. The supernatants were obtained after a 3000 3 g centrifugation at 48C for 10 min. The protein concentration was determined with the BCA assay (Pierce), and samples were stored at À808C.
Western Blot Analysis
Crude membrane-containing homogenates of maternal kidney, placenta, fetal brain, and intestine (20 lg) were incubated with sample buffer at room temperature for 30 min and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5% and 10% polyacrylamide gel for OCT3 and MATE1, respectively. After the proteins were transferred to a polyvinylidene difluoride membrane (Bio-Rad), the membrane was blocked for 1 h with 5% nonfat dry milk in Tris-buffered saline containing 0.05% Tween 20 (TBST). The membranes were then incubated with primary antibodies for 1 h at concentrations of 1:1000 and 1:100 for OCT3 and MATE1, respectively. Then the membranes were washed four times with TBST and incubated for 1 h with a horseradish peroxidase-linked donkey anti-rabbit IgG antibody at concentrations 1:2000 and 1:200 for OCT3 and MATE1, respectively. After washing with TBST buffer, the membranes were developed using enhanced chemiluminescent reagent (GE Healthcare) and subjected to autoluminography for 1-5 min. The immunoreactive bands on the exposed films were quantified as described previously [19] . Equal loading of proteins onto the gel was confirmed by immunodetection of b-actin.
Immunohistochemistry
Preparations of the placental tissues on gds 12, 15, 18, and 21 were performed as described previously [8] . Specimens of the placenta were fixed in 4% paraformaldehyde and then paraffin-embedded for immunohistochemistry. Sections of the placenta (thickness, 7 lm) were rehydrated through a series from xylene to ethanol solutions. The antigen OCT3 and MATE1 were unmasked by heating the specimens in sodium citrate buffer (pH 6.0) in a microwave oven at 750 W. Blocking of nonspecific background staining was performed with 10% normal goat serum (Sigma-Aldrich) in phosphate-buffered saline (pH 7.4) for 30 min. Slides were incubated for 1 h at room temperature with polyclonal primary antibody rabbit anti-rat Oct3 (Alpha Diagnostic) diluted 1:50 in bovine serum albumin (BSA). Likewise, the slides were incubated for 1 h at room temperature with primary antibody rabbit anti-rat Mate1 (Santa Cruz Biotechnology) diluted 1:50 in BSA. Endogenous peroxidase activity was blocked with 3% H 2 O 2 in PBS solution for 15 min. Subsequently, the slides were developed for 30 min with a secondary antibody-goat anti-rabbit IgG conjugated to peroxidase-labeled polymer (DAKO EnVision þ ) in the presence of rat IgG (Sigma-Aldrich) diluted 1:50 in substrate buffer. The reaction was visualized using diaminobenzidine (DAB substrate-chromogen solution; DAKO), and the sections were counterstained by hematoxylin. The specificity of the immunostaining was assessed by staining with nonimmune isotype-matched immunoglobulins. The MATE1 immunohistochemistry was performed in the same manner.
Photo documentation and image digitizing were performed using Olympus AX 70 with a digital firewire camera Pixelink PL-A642 (Vitana Corp.) and image analysis software NIS (Laboratory Imaging).
Fetal Exposure to MPP þ During Pregnancy
The jugular vein (for the injection of radioisotope) and the carotid artery (for blood sampling) of pregnant rats on gds 12, 15, 18, and 21 were cannulated after anesthetizing the rats [20] . The rats were infused for 60 min with a solution containing 1.48 lg of MPP þ in 1 ml of physiological solution including trace amount of radiolabeled [
H] MPP
þ ; 1 ml of this solution was injected as a loading dose at the beginning of the infusion. The steady state, as determined by maternal blood sampling, was reached 40 min after the beginning of the experiment. The concentration of MPP þ in the maternal blood at the steady state ranged from 50 to 80 nM, which is well below the saturating concentration [8] .
At the end of the infusion (60 min), the animals were sacrificed, and one to three randomly selected fetuses of each dam were sampled. On gds 18 and 21, the fetal brain, kidney, liver, and intestine from three fetuses were excised. Fetal tissue and blood samples were treated with tissue solubilizer Solvable (PerkinElmer Life and Analytical Sciences), and after mixing with scintillation liquid (PerkinElmer Life and Analytical Sciences), their radioactivity was measured (Tri-Carb 2900TR; Perkin Elmer). The amount of MPP þ that reached the fetus was expressed as the feto-maternal ratio of the radioactivity of 
Statistical Analysis
The animal experiments are based on four rats (n ¼ 4) for each stage of gestation. The number of the human placenta samples was n ¼ 7 (first trimester) and n ¼ 10 (third trimester). All the results are presented as means 6 SD. Assuming nonnormal data distribution, nonparametric permutation test was used to assess statistical significance [21, 22] . P , 0.05 was considered statistically significant.
RESULTS
Oct1, Oct2, Oct3, Mate1, and Mate2 mRNA Expression in the Rat Placenta and Fetal Tissues at Different Stages of Gestation
The mRNA levels of Oct and Mate isoforms in the placentas and fetal organs at different stages of gestation (gds 12, 15, 18, and 21) as evaluated by qRT-PCR analysis are shown in Figures 1-3 . All the Oct isoforms were detected in the rat placenta on all the gds (Fig. 1A) . While the levels of Oct1 and Oct2 remained constant throughout gestation, Oct3 mRNA levels increased significantly toward the end of gestation, reaching values almost nine times higher in the term placenta compared with those on gd 12 (Fig. 1A) . Similarly, both Mate1 and Mate2 mRNA were expressed on all the gds but only Mate1 levels increased during gestation, reaching values almost 17 times higher in the term placenta compared with those on gd 12 (Fig. 1B) . Mate2 levels, on the other hand, remained unchanged throughout gestation (Fig. 1B) .
In the fetal organs, the highest expression of Oct1 was detected in the liver and kidney with significant increase between gd 18 and 21 ( Fig. 2A) . Oct2 mRNA was highly expressed in the fetal brain and kidney with increase in the expression from gd 18 to 21 (Fig. 2B) . Oct3 was found to be OCT3 AND MATE1 IN PLACENTA DURING PREGNANCY highly expressed in the fetal brain while its expression in other organs was relatively low. Furthermore, its levels on gd 21 were almost five times higher than those on gd 18 (Fig. 2C) . The highest expression of Mate1 was observed in the fetal kidney; again, its levels increased from gd 18 to 21 approaching those of the adult maternal kidney (Fig. 3A) .
Mate2 was found to be expressed predominantly in the fetal brain compared with other fetal organs with increasing trend from gd 18 to 21 (Fig. 3B) .
OCT1, OCT2, OCT3, MATE1, and MATE2 mRNA Expression in the First Trimester and Term Human Placenta
The mRNA expression of OCT and MATE isoforms in the human placenta as evaluated by qRT-PCR is shown in Figure  4 . In the first trimester placenta, expression of all the genes of interest was detected, however, with a relatively high level of variability. In the term placenta, we were not able to detect MATE1 mRNA expression while MATE2 mRNA expression was observed. Comparing expression of OCT and MATE isoforms between first trimester and term placentas, statistically significant decreases were observed for OCT2, OCT3, and MATE1 (Fig. 4) .
Western Blot Analysis of OCT3 and MATE1 Transporters in the Rat Placenta and Fetal Tissues at Different Stages of Gestation
Protein quantification was performed in homogenates of the maternal kidney, placenta, fetal brain, and intestine (Figs. 5 and 6). The relative amount of OCT3 and MATE1 protein was expressed as a percentage of the maternal kidney values. The OCT3 and MATE1 protein expression in the placenta showed 
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an increasing trend toward the end of gestation, reaching 1.88-and 1.63-fold higher levels on gd 21 as compared to gd 12, respectively (Fig. 5, A and B ). An almost 1.4-fold increase in OCT3 protein expression in the fetal brain was observed from gd 18 to 21 (Fig. 6A) .
Immunohistochemical Localization of OCT3 and MATE1 in the Rat Placenta at Different Stages of Gestation
The expression patterns of OCT3 and MATE1 in the rat placenta as investigated by immunohistochemistry at the light microscopy level are shown in Figures 7 and 8 . On gd 12, MATE1 and OCT3 staining patterns were similar; the staining was detected in the cytoplasm of giant cells and in trophoblast cells in the area of the forming labyrinth area. A similar pattern was also detected on gd 15; OCT3 and MATE1 positive responses were shown in the cytoplasm of giant cells and in trophoblast cells in the area of the forming labyrinth zone but not in fetal capillaries (Figs. 7 and 8) . On gd 18, OCT3 and MATE1 staining was very weak in giant cells because giant cells disappear from the placenta during gds [17] [18] [19] . A strong positive OCT3 response was detected in the labyrinth area (Fig.  7) . Staining was predominantly visible in layers II and III of syncytiotrophoblast but was not visible in layer I (Fig. 7) . MATE1 staining was also visible in syncytiotrophoblast but it was not possible to differentiate the exact layer in which it was expressed (Fig. 8) . No OCT3 and MATE1 positive responses OCT3 AND MATE1 IN PLACENTA DURING PREGNANCY were detected in fetal capillaries (Figs. 7 and 8) . On gd 21, the OCT3 response was almost exclusively detected in syncytiotrophoblast of the labyrinth area, namely in layer II and III of trophoblast cells (Fig. 7) . MATE1 staining was also visible in syncytiotrophoblast, however, their precise localization with respect to the layers was not possible (Fig. 8) . No MATE1 and OCT3 staining was detected in fetal capillaries in the labyrinth zone and spongiotrophoblast (Figs. 7 and 8) .
Transport of MPP
þ Across the Rat Placenta and Its Distribution in Fetal Tissues at Different Stages of Gestation
MPP
þ was infused intravenously into pregnant rats at gd 12, 15, 18, or 21; its concentrations at steady state, as determined by maternal blood sampling, were measured in fetal tissues and compared to those in the maternal plasma. The highest amount of MPP þ crossed the placenta and reached the fetus on gd 12; after that, a significant drop in fetal exposure to maternal MPP þ was recorded. The amount of MPP þ reaching the fetus on gds 15, 18, and 21 was approximately 10-fold lower than on gd 12 (Fig. 9) , suggesting greater protection of the fetus against maternal MPP þ beyond gd 12. In the fetal tissues, MPP þ was detected in all the organs tested, that is, the kidney, liver, intestine, and brain.
DISCUSSION
Transporter proteins in the placenta are involved in the regulation of fetus exposure to xenobiotics by selectively transporting toxic substrates between maternal and fetal circulations. Many ABC and SLC transporters have been found to be functionally expressed in the placenta [1] ; it is thus obvious that detailed understanding of the role of these transporters in transplacental pharmacokinetics is crucial for the assessment of the risk of fetal drug exposure and toxicity. To date, SLC transporters have mainly been investigated in the excretory organs, such as kidney and liver [5, 23] , but relatively little attention has been paid to their expression and function in the placenta. In our previous report, we described the synchronized activity of two SLC transporters, OCT3 and MATE1, in the passage of MPP þ across the rat term placenta [8] . Since changes in transporter expression during pregnancy are of great importance, the objectives of this follow-up study were to quantitatively determine the expression, localization, and function of OCT and MATE isoforms in the placenta and fetal tissues at different stages of gestation.
OCTs are facilitative diffusion systems that transport organic cations in a bidirectional manner across the plasma membrane [3] . Of all the isoforms, OCT3 (also known as the extraneuronal monoamine transporter and encoded by the SLC22A3 gene) shows very high expression in the placenta of all the species tested [8, 9, [24] [25] [26] [27] , suggesting that OCT3 is a placenta-specific OCT. It was found to be localized to the basolateral, fetus-facing, membrane of the trophoblasts in the human [26] and rat [8] placenta. Based on RT-PCR quantification, we confirm in this study the abundant expression of OCT3/Oct3 in both the human and rat placenta. However, when investigating changes in placental expression of OCT3/Oct3 mRNA at different stages of gestation, opposite trends were observed in the human and rat. In the human placenta, OCT3 expression declined from first trimester to term; on the other hand, in the rat placenta, Oct3 expression showed an increasing trend toward the end of gestation. Similar interspecies differences in the profiles of transporter expression throughout pregnancy have previously been observed for other placental transporters, for example, P-glycoprotein [28] or BCRP [29] . This issue is still controversial, however, as many research groups reach different conclusions. It is obvious from our data that SLC transporter expression follows different regulation schemes in rat and human placentas, suggesting different fetal protective mechanisms between species. The regulation steps are not known to date; what is clear, however, is that these differences should be borne in mind when extrapolating animal data to human conditions. MATE transporters have been discovered recently and have been described as H þ /organic cation antiporters [7] . Despite belonging to the SLC family of transporters, they function as efflux proteins and often couple with OCTs in excretory organs, such as kidney and liver. To date, placental expression of Mate1 has been revealed only in the rat [8, 30] ; negligible or zero expression of Mate1/MATE1 mRNA was detected in the murine [31, 32] or human term placenta [7] , raising the question as to the mechanism of transplacental transport of organic cations in these species (see, e.g., [30, 33] ). We believe a common consensus on MATE1 expression and function in the human placenta is yet to be reached. While our data are consistent with Otsuka and colleagues' [7] findings with respect to negligible expression of MATE1 in the term placentas, we analyzed also immature placentas, observing MATE1 expression in the first trimester placentas and MATE2 expression in the first and third trimester placentas. We, therefore, speculate that vectorial transport of organic cations across the placenta recently described in rat [8] may be mediated by a OCT3-MATE1/2 pathway also in human. However, further studies are required to elucidate this issue in detail.
Protein analyses by Western blots and immunohistochemical visualization were in a reasonable agreement with the gene expression studies. The trends in protein expression of placental OCT3 and MATE1 throughout gestation were similar to those of Oct3 and Mate1 mRNA; although the differences were less pronounced, they still reached statistical significance thus confirming the increase in placental OCT3 and MATE1 toward the end of gestation. Consistent with our previous study [8] , immunohistochemical visualization on gd 21 showed OCT3 expression preferentially localized to the fetal side and MATE1 to the maternal side of the trophoblast cells but not in fetal capillaries. During earlier stages of pregnancy (gds 12 and 15), we detected OCT3 and MATE1 expression in the giant cells and trophoblast cells in the area of the forming placental labyrinth. As pregnancy proceeds, giant cells disappear from the placenta, and the staining on gds 18 and 21 was detected only in the syncytiotrophoblast in the labyrinth zone. In human placenta, the techniques for proteomic analyses were not available and protein expression/function data need to be elucidated in further studies; nevertheless, because mRNA expression is often an excellent proxy for the presence of a protein [34] , it is reasonable to assume the expression and function of OCT and MATE transporters on the materno-fetal interface of the human placenta.
MPP þ is a model toxin and a well-established substrate of OCT3 [26, 27] and MATE1 [35] . Furthermore, it is not subject to metabolic degradation [36] , which makes it a suitable model compound for functional analysis of OCT and MATE transporters. In our previous study, using dually perfused rat term placenta, we described OCT3-MATE1-mediated transport of MPP þ in the fetal-to-maternal direction even against a concentration gradient [8] . We concluded that placental OCT3-MATE1 form an efficient excretory pathway for cations, OCT3 AND MATE1 IN PLACENTA DURING PREGNANCY similar to the kidney or liver, and play an important role in fetal protection and detoxification. However, the drawback of experiments using perfused placenta is that they can be performed only on the last day of gestation. To extend our knowledge beyond the final phase of pregnancy and to investigate the protective role of placental OCT3 and MATE1 also at earlier gestational stages, in this paper, we infused MPP þ intravenously into mothers at different stages of gestation and measured at the steady state the MPP þ concentration in the fetal tissues. We observed significant leakage of MPP þ into fetal tissues only in the midgestational stage, that is, on gd 12. From 15 gd onward, relatively low levels of MPP þ were detected in the fetuses (Fig. 9 ). These findings indicate that the fetus is more vulnerable to cationic compounds in maternal circulation in the first half of pregnancy. As pregnancy proceeds, the protective role of the placenta against organic cations increases; we believe this is due to maturation of both active and passive components of the placenta, that is, higher expression of placental OCT3/MATE1 transporters as observed in this study, as well as increasing compactness of the placental tissues.
Once in the fetal compartment, the fate of MPP þ or other toxic cations may be partly controlled by the expression of SLC transporters in the fetal tissues. Therefore, in this study, we investigated the expression of OCT and MATE transporters in the developing fetus. Near term, significant levels of Oct and Mate isoforms were detected in the fetal excretory organs with similar patterns to those described in adults, that is, Oct1 was detected mainly in the kidney and liver while Oct2 and Mate1 were detected predominantly in the kidney. These observations suggest some capacity of the fetus to eliminate organic cations through its kidney and liver. However, in addition to excretory organs, Oct2, Oct3, and Mate2 showed significant expression in the fetal brain. These findings, on the other hand, indicate the possibility of MPP þ crossing the blood-brain barrier, which was confirmed in our study by accumulation of maternally administered MPP þ in the fetal brain. In addition, central nervous system toxicity (Parkinson's disease) after administration of MPP þ or its precursor, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to pregnant dams has previously been reported in rats [37] and mice [38, 39] . On gd 15, MATE1 staining was detected in trophoblast cells (arrowheads) but not in fetal capillaries in the forming labyrinth zone. Similar staining patterns for MATE1 were visible on gds 18 and 21. MATE1 expression was visible in the syncytiotrophoblast in the labyrinth zone (arrowheads); however, precise localization with respect to layers was not possible. No staining was visible in fetal capillaries. M, maternal blood space; F, fetal blood space. The slides were counterstained with hematoxylin. Bars ¼ 100 lm (12 gd) and 10 lm (15, 18, and 21 gds).
In conclusion, it is apparent that throughout gestation both the placenta and fetus express OCT and MATE transporters in a dynamic manner. In the rat placenta and fetal tissues, expression of OCT3 and MATE1 tends to increase toward the end of gestation. This fact, along with the general maturation of the placental tissue results in significantly lower transport of MPP þ across the placenta from mother to fetus after gd 12. In contrast, human placenta shows decreasing expression of OCT2, OCT3, and MATE1 mRNA, suggesting these transporters may play a role in fetal protection preferentially at earlier stages of gestation.
